Acetyl-L-Carnitine In Severe Hepatic Encephalopathy
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
To assess the clinical efficacy of ALC in the treatment of severe hepatic encephalopathy
(grade 3 of the West Haven grading scale), we performed a randomised, double blind
placebo-controlled study administering ALC to cirrhotic patients, evaluating the effects on
ammonia levels and performance in cognitive functions.